---
title: "Kymera Therapeutics posts corporate deck outlining push to develop oral targeted protein degraders for immunology"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294964332.md"
description: "Kymera Therapeutics outlined its strategy to commercialize oral targeted protein degraders for immunology, aiming to combine biologics-like efficacy with pill convenience. Key assets include KT-621 (STAT6 degrader) for Type 2 inflammatory diseases, with Phase 2b atopic dermatitis data expected by late 2026 and Phase 3 trials starting mid-2027. Additionally, KT-579 (IRF5 degrader) targets lupus, with Phase 1 data due in Q4 2026. The partnered pipeline features KT-485 (IRAK4) and KT-200 (CDK2)."
datetime: "2026-08-05T12:09:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294964332.md)
  - [en](https://longbridge.com/en/news/294964332.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294964332.md)
generator: "portal-rs"
---

# Kymera Therapeutics posts corporate deck outlining push to develop oral targeted protein degraders for immunology

-   Kymera outlined a strategy to commercialize oral targeted protein degraders in immunology, aiming to match biologics-like activity with pill convenience. \* Lead asset KT-621, an oral STAT6 degrader, positioned for dupilumab-like efficacy across Type 2 inflammatory diseases; Phase 2b atopic dermatitis data due by year-end 2026. \* Phase 3 atopic dermatitis trials planned to start by mid-2027; Phase 2b asthma readout targeted for late 2027. \* Second wholly owned program KT-579, an IRF5 degrader, targets lupus and related autoimmune diseases; Phase 1 healthy-volunteer data expected in 4Q26. \* Partnered pipeline includes KT-485, an IRAK4 degrader with an IND targeted for 2027, alongside KT-200, a CDK2 degrader for solid tumors. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [KYMR.US](https://longbridge.com/en/quote/KYMR.US.md)

## Related News & Research

- [Kymera Therapeutics (KYMR) Stock Faces A Revenue Durability Reckoning](https://longbridge.com/en/news/295087176.md)
- [Gentian Diagnostics hosts webinar on circulating calprotectin use in rheumatic disease management](https://longbridge.com/en/news/296439040.md)
- [11:39 ETJiMMYBAR! Expands into Sam's Club with Nationwide Online Availability and California Club Rollout](https://longbridge.com/en/news/296377299.md)
- [Volare opens commercial-scale insect protein plant in Pori with EUR 15 million investment](https://longbridge.com/en/news/296203318.md)
- [One Platform, Every Ailment: Hinge Health's Gamble](https://longbridge.com/en/news/296483875.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**